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To study the association between peripheral blood metabolic and inflammatory factors and
presence of diabetic macular edema (DME) and its related anatomic features in type 2 dia-
betic mellitus (T2DM) patients.
Material and methods
Observational cross-sectional study on a proof of concept basis. Seventy-six T2DM
included patients were divided based on the presence (n = 58) or absence of DME (n = 18)
according to optical coherence tomography (OCT). Ultra-widefield fluorescein angiography
(UWFA) was performed in DME patients. Fasting peripheral blood sample testing included
glycemia, glycated hemoglobin, creatinin and lipid levels among others. Serum levels of a
broad panel of cytokines and inflammatory mediators were also analysed. OCT findings
included central subfoveal thickness, diffuse retinal thickness (DRT), cystoid macular
edema (CME), serous retinal detachment and epirretinal membrane. UWFA items included
pattern of DME, presence of peripheral retinal ischemia and enlarged foveal avascular zone
(FAZ).
Results
Metabolic and inflammatory factors did not statistically differ between groups. However, sev-
eral inflammatory mediators did associate to certain ocular items of DME cases: IL-6 was
significantly higher in patients with DRT (p = 0.044), IL-10 was decreased in patients with
CME (p = 0.012), and higher IL-8 (p = 0.031) and VEGF levels (p = 0.031) were observed in
patients with enlarged FAZ.
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Conclusion
Inflammatory and metabolic peripheral blood factors in T2DM may not be differentially asso-
ciated to DME when compared to non-DME cases. However, some OCT and UWFA fea-
tures of DME such as DRT, CME and enlarged FAZ may be associated to certain systemic
inflammatory mediators.
Introduction
Diabetic retinopathy (DR) is the most common microvascular complication of Diabetes Melli-
tus (DM) and is characterized by progressive retinal microvascular changes leading to tissue
ischemia, increased permeability, neovascularization and edema.[1] If such changes affect the
central area of the retina (macula), diabetic macular edema (DME) is developed. DME is the
leading cause of decreased visual acuity in patients with DR, and its overall prevalence in DM
patients is about 6.8%~14%.[2–4] Natural history of DME can cause significant vision loss in
up to 50% of affected patients at two years time.[5] Type 2 DM (T2DM) is the most prevalent
form of DM and about 3% of them do present DME 5 years after being diagnosed, but such a
proportion dramatically increases with disease duration, reaching 28% at 20 years time.[6]
The pathogenesis of DME in T2DM is thought to be associated with increased vascular per-
meability due to breakdown of the blood–retinal barrier (BRB) and the blood–aqueous barrier.
This breakdown is driven by the inflammation and oxidative stress produced by high levels of
advanced glycation end-products.[7] Such events present with characteristic cellular and func-
tional changes due to inflammation taking place in DR: leukostasis, abnormal leuckocyte
adherence and increased permeability of retinal vascular barriers.[8] This global systemic
inflammatory environment has been widely studied in diabetic patients. [8–12] However, it
remains unclear whether the pathophysiology of DME is mainly attributed to such systemic
affection or to a local (intraocular) response.
Several studies have published reports on systemic levels of metabolic and inflammatory
mediators in DR but little is specifically known on DME. DR has been associated to higher
serum levels of several cytokines, chemokines, growth and angiogenic factors such as inter-
leukin (IL)-1β, IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), tumor necrosis fac-
tor-alpha (TNF-α) and vascular endothelial growth factor (VEGF).[13–15] Metabolic and
cardiovascular-related factors, such as poor glycemic control, blood hypertension, microalbu-
minuria, pregnancy, dyslipidemia, smoking habit and sedentary living have been also associ-
ated to DR development and progression.[11] However, there are only few studies focusing on
systemic metabolic factors in DME, [16–19] and systemic inflammatory mediators in DME
have not been studied so far. Inflammatory and vascular mediators in DME have been only
studied locally in its intraocular setting. Indeed, it has been shown that DME patients have
increased levels of pro-inflammatory mediators in aqueous humour (AH) compared to non-
DME cases. [20] It is therefore controversial whether DME is also specifically associated to cer-
tain serum inflammatory and metabolic factors.
Finally, current diagnostic techniques on DME have greatly evolved from those used in past
studies on systemic factors related to this entity. Optical coherence tomography (OCT) is a
light-based imaging technique with no side events that allows tomographic reconstruction of
any tissue, enabling, for example, characterization of cysts and extracellular edema within the
macula. Ultra-widefield fluorescein angiography (UWFA) enhances visualization of retinal
vessels and tissue ischemia up to 200˚ of photography of the retina (compared to the standard
form of 45˚). Both techniques have not been widely used in previous studies on this topic.
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Given the current state of understanding of the complex systemic inflammatory and meta-
bolic events in DM, we focused our research on DME. Although much reported information
exists on differentiated levels of intraocular mediators of inflammation in diabetic patients
with DME, little is known regarding such molecules in peripheral blood. Moreover, some
reports on DME and its association to systemic items have not used current modern imaging
techniques to identify DME such as OCT and UWFA. Therefore, the goal of the present study
was to describe the association between peripheral blood metabolic and inflammatory factors
and presence of DME and its related anatomic features in T2DM patients.
Material and methods
Study design
We present an observational cross-sectional study assessing serum levels of inflammatory and
metabolic mediators in T2DM patients with and without DME.
The Hospital Clinic of Barcelona Institutional Review Board (IRB) approved this study
according to local and national IRB guidelines. All DME and non-DME patients provided
written informed consent, and the research followed the tenets of the Declaration of Helsinki.
Eighty consecutive patients were screened when first attended in the Eye Department (Hospi-
tal Clı´nic of Barcelona, Spain) after primary care ophthalmologist referral because of DR with
presumptive DME. Exclusion criteria was limited to proliferative DR (PDR), unclear ocular
media, other retinal vasculopathy (such as retinal arterial or vein occlusion), pregnacy, sys-
temic diseases of autoimmunitary or infectious condition, and systemic immunosupressive
treatment of any kind. Whenever bilateral DME was present, the eye with the thickest edema
in the fovea according to OCT measurements in microns was selected as the study eye.
All assessments and explorations, as well as peripheral blood extraction, were carried out
the same day and in the same localiton; only UWFA could be delayed up to one week since
inclusion date. Clinical assessment involved a complete medical and treatment history includ-
ing DM duration.
Cytokine and metabolic profile determination
Peripheral blood extraction was carried out at fasting time and included two samples simulta-
neously collected to determine serum levels of metabolic parameters and inflammatory mark-
ers respectively. For serum obtention, blood was centrifugated at 1600g within 30 minutes
after obtention and stored at -70˚C until inflammatory mediators were determined.
Searched metabolic parameters included glycemia, creatinin, total cholesterol, low-density
lipoproteins cholesterol (LDL-C), high-density lipoproteins cholesterol (HDL-C), triglycerides
(TG), aspartat aminotransferase (AST), alanine aminotransferase (ALT), hemoglobin (Hb)
and glycated Hb (HbA1C). Such parameters analyses were carried out in regular facilities of the
study-based terciary referral center. Ten immune mediators were determined: proinflamma-
tory molecules such as IL-1β, IL-3, IL-6, IL-8, MCP-1, interferon gamma-induced protein-10
(IP-10); type 1 cytokines such as interferon gamma (IFN-γ) and TNF-α; type 2 cytokines (IL-
10); and growth factors (VEGF). These molecules were chosen based on published results of
previous studies regarding both serum and intraocular inflammatory biomarkers in DR and
DME.[13–15, 20, 21] Selected immune mediators were determined by a Luminex platform
(Millipore’s MilliPlex Human Cytokine/ Chemokine kit) used to measure cytokine and che-
mokine levels in serum samples using an assay plate layout consisting of seven standards in
duplicate (3.2–2000 pg/mL), one blank well (for background fluorescence subtraction), two
internal quality control samples in duplicate and 25 μL duplicates of each serum sample. The
MilliPlex method was performed as recommended by the manufacturer.
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Ophthalmologic assessment
Ophthalmologic assessment was also performed including past and current ophthalmic events
and treatments and a complete eye examination was carried out with visual acuity determina-
tion, slit lamp biomicroscopy, intraocular pressure assessment and funduscopy under pupil
dilation. Eye fundus exploration included DR grading according to international-based scale:
[1, 22] mild non-proliferative DR (NPDR), moderate NPDR, severe NPDR and PDR. All sub-
jects underwent macular OCT exploration (Cirrus, Carl-Zeeis Meditec, Inc, Dublin, CA) as
gold-standard determination of DME using a standard Macular Cube 518x128 μm scan. Those
diagnosed of DME were in addition studied with UWFA (Optomap, Optos PLC, Dunfermline,
Scotland, UK). OCT findings included quantitative determination of central subfoveal thick-
ness (CST) and qualitative findings (Fig 1) as presence of diffuse retinal thickening (DRT),
cystoid macular edema (CME), serous retinal detachment (SRD) and epirretinal membrane
(ERM). DME was OCT-confirmed when one of the next items was found:[23] CST>250μm,
DRT, CME and/or SRD. UWFA findings (Fig 2) included: diffuse or focal pattern of DME
according to common practice criteria [24] and previously published reports;[25] increased
foveal avascular zone (FAZ) as defined by prior studies (>0.32mm2);[25] and presence of
peripheral retinal ischemia (PRI) set as areas of capillary nonperfusion outside retinal vascular
arcades.
Statistical analysis
Description of variables were showed by mean, median, interquartilic range (percentiles 25th
and 75th) and absolute range for quantitative variables. Absolute frequencies and percentages
were used in the description of qualitative factors. Inferential analyses were performed using
Mann-Whitney U test. A billateral type I error of 5% was stablished. Analyses were first per-
formed comparing DME patients with non-DME patients. On the other hand, analyses were
carried out within the DME group of patients based on qualitative endpoints (for example,
comparing CME cases with non-CME ones). Due to observational characteristics of the pres-
ent study a strategy for multiplicity adjust was not planned, thus significant results should be
validated in posterior independent studies. All statistical calculations were executed on SPSS
v.20.0 (SPSS IBM Corporation, New York, NY, USA).
Results
Eighty DM patients were included in the study according to previously stated criteria. Four
patients were finally excluded due to blood sample processing malfunction and no possible
determination of inflammatory markers. Seventy-six patients were finally analysed. Fifty-
eight of them presented DME according to OCT-based defined endpoints. Eighteen patients
referred for suspected DME did not achieve such endpoint and therefore constituted the non-
DME group. All included patients had peripheral venous blood extraction and OCT explora-
tion made. Of 58 DME patients, 42 subjects (72%) underwent UWFA according to study
protocol; 16 patients did not undergo UWFA due to delayed planning or refusal (Fig 3).
Demographics of both groups (Table 1) reported no differences between age, gender and DM
duration. Regarding DR grading, all non-DME cases (n = 18) showed signs of mild NPDR
whereas DME cases presented mild NPDR in 25 cases (43%), moderate NPDR in 22 subjects
(38%) and severe NPDR in 11 cases (19%).
No statistically significant differences were found between DME and non-DME patients on
metabolic blood parameters (glycemia, creatinin, total cholesterol, LDL-C, HDL-C, TG, AST,
ALT, Hb and HbA1C) and serum inflammatory biomarkers (IL-1β, IL-3, IL-6, IL-8, IL-10,
MCP-1, IP-10, IFN-γ, TNF-α and VEGF) (Table 1).
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Fig 1. Examples of OCT-associated items. (A) No DME. (B) Diffuse retinal thickening. (C) Cystoid macular
edema. (D) Serous retinal detachment. (E) Epirretinal membrane.
https://doi.org/10.1371/journal.pone.0173865.g001
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Anatomic findings associated to DME as OCT and UWFA findings are shown in Table 2. A
subanalysis of the DME patients was done according to an arbitrary split point of CST as an
explorative clinical marker of mild (<450μm) or severe (450μm) DME presentation. Such
split point was proposed by the authors on a proof of concept basis as an intended marker of
DME severity. No statistically significant differences were found regarding blood parameters
and inflammatory factors between such groups. However, BCVA (logMAR) did statistically
Fig 2. Examples of UWFA-based items (doted lines). (A) Color fundus photography of NPDR case without DME nor any associated sign. (B) UWFA of
previous case. (C) focal-pattern DME. (D) diffuse-patern DME. (E) increased FAZ. (F) PRI.
https://doi.org/10.1371/journal.pone.0173865.g002
Fig 3. Flowchart of the study design.
https://doi.org/10.1371/journal.pone.0173865.g003
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Table 1. Clinical parameters of patients with and without DME.
No DME (n = 18) DME (n = 58) p-value
Demographics:
Age (years) 65 [59; 76] 70 [62; 78] 0.264
32 to 88 53 to 85
Gender
Male (%) 13 (72.2%) 34 (58.6%) 0.408
Female (%) 5 (27.8%) 24 (41.4%)
DM duration (years) 11 [8; 14] 11 [8; 19] 0.344
1 to 25 4 to 40
Serum metabolic markers:
Glucose (mg/dl) 191 [128; 264] 146 [116; 213] 0.220
62 to 341 51 to 417
Creatinine (mg/dl) 0.84 [0.68; 0.96] 0.87 [0.77; 1.03] 0.330
0.54 to 1.34 0.37 to 4.13
Total cholesterol (mg/dl) 184 [148; 200] 172 [150; 193] 0.545
95 to 281 90 to 249
Triglyceride (mg/dl) 116 [85; 204] 112 [85; 172] 0.648
49 to 832 43 to 359
AST (U/L) 20 [17; 28] 20 [16; 26] 0.402
15 to 69 8 to 78
ALT (U/L) 22 [19; 28] 21 [15; 29] 0.250
15 to 106 6 to 119
LDL-C (mg/dl) 106 [79; 128] 99 [76; 119] 0.641
56 to 159 38 to 175
HDL-C (mg/dl) 40 [34; 47] 44 [37; 59] 0.104
22 to 68 24 to 84
Hb (mg/dl) 145 [127; 155] 136 [124; 148] 0.288
119 to 159 98 to 175
HbA1C (%) 8.3 [8; 9.4] 7.7 [6.9; 8.9] 0.082
6.1 to 13.3 5.5 to 13.8
Serum inflammatory markers:
IL-1β (pg/ml) 0.8 [0.8; 0.8] 0.8 [0.8; 0.8] 0.753
0.8 to 3.71 0.8 to 6.90
IL-3 (pg/ml) 0.7 [0.7; 0.7] 0.7 [0.7; 0.7] 1
0.7 to 0.7 0.7 to 162.15
IL-6 (pg/ml) 0.9 [0.9; 1.53] 0.9 [0.9; 0.9] 0.258
0.9 to 25.91 0.9 to 81.14
IL-8 (pg/ml) 8.23 [5.38; 10.72] 8.78 [4.19; 12.60] 0.842
2.06 to 25.19 0.82 to 108.03
IL-10 (pg/ml) 1.1 [1.1; 1.1] 1.1 [1.1; 1.1] 0.741
1.1 to 33.74 1.1 to 12.12
MCP-1 (pg/ml) 401.73 [323.08; 458.65] 421.29 [361.56; 547.26] 0.465
249.65 to 656.79 143.94 to 1115.98
IP-10 (pg/ml) 254.95 [189.66; 378.41] 206.6 [140.91; 366.42] 0.266
128.54 to 808.90 45.61 to 1271.69
IFN-γ (pg/ml) 1.18 [0.8; 4.3] 0.89 [0.8; 3.42] 0.477
0.8 to 58.31 0.8 to 572.05
TNF-α (pg/ml) 5.74 [4.27; 8.19] 7.58 [5.23; 10.24] 0.078
(Continued )
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significantly differ (p<0.001) between them with better visual acuity found in mild DME cases
(median 0.3 [IQR: 0.1; 0.5]) thant severe ones (median 0.7 [IQR 0.5; 0.8]).
Regarding further analysis within the DME group, metabolic and inflammatory markers
were compared according to OCT and UWFA anatomic findings (S1 Table and S2 Table
respectively). Statistically significant associations are reported in Table 3 and shown in Fig 4.
DME patients presenting with DRT (n = 22) were therefore related (p = 0.044) to higher IL-6
peripheral blood serum levels. Cases of CME in the OCT exploration (n = 38) were associated
(p = 0.012) to lower IL-10 concentration. Finally, significant differences were also found
regarding DME patients with enlarged FAZ (n = 6) showing higher serum levels of IL-8
(p = 0.031) and VEGF (p = 0.031) when compared to those with physiological FAZ.
Discussion
This cross-sectional study aimed to analyse serum inflammatory and metabolic factors (cyto-
kines, growth factors, and common practice metabolic items) and their association to DME in
first place and, in addition, their relation to ophthalmic anatomic features studied by latest cut-
ting-edge technology.
As a whole, no statistically significant differences were found in all parameters between the
DME and the non-DME group (Table 1). At first glance, one could at least expect HbA1C to be
Table 1. (Continued)
No DME (n = 18) DME (n = 58) p-value
1.75 to 10.61 0.7 to 33.06
VEGF (pg/ml) 26.3 [26.3; 293.59] 26.3 [26.3; 274.69] 0.631
26.3 to 717.13 26.3 to 3269.42
Variables are described by median and interquartilic range [Percentiles 25th, 75th] and absolute range, except from gender.
Abbreviations: ALT, alanine aminotransferase; AST, aspartat aminotransferase; Hb, hemoglobin; HbA1C, glycosylated hemoglobin-A1; HDL-C, high-
density lipoproteins cholesterol; IL, interleukin; IP-10, interferon gamma-induced protein-10; IQR, interquartilic range; LDL-C, low-density lipoproteins
cholesterol; MCP-1, monocyte chemoattractant protein-1; SD, standard deviation; TNF-α, tumour necrosis factor alpha; VEGF, vascular endothelial growth
factor.
https://doi.org/10.1371/journal.pone.0173865.t001
Table 2. OCT and UWFA findings of DME.
n (%)
OCT:
CST <450μm 33 (57)
CST450μm 25(43)
Diffuse retinal thickening 22 (38)
Cystoid macular edema 38 (65)
Serous retinal detachment 7 (12)
Epirretinal membrane 4 (7)
UWFA:
Diffuse-pattern DME 14 (33)
Focal-pattern DME 28 (66)
Increased foveal avascular zone 6 (14)
Peripheral retinal ischemia 11 (26)
Abbreviations: CST, central subfoveal thickness; DME, diabetic macular edema; OCT, optical coherence
tomography; UWFA, ultra-widefield fluorescein angiography.
https://doi.org/10.1371/journal.pone.0173865.t002
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higher in the DME group according to the general understandig of this DM complication.[11,
17] However, studied non-DME patients were indeed referred patients with DR and no DME
confirmed by fundus and OCT examination. Non-DME patients could therefore deploy a
worse metabolic peripheral blood profile than similar non-DME DM outclinic patients not
Table 3. Inflammatory factors associated to OCT and UWFA findings of DME.
OCT and UWFA finding p-value
DRT (n = 22) no DRT (n = 36)
IL-6 (ρg/ml) 6.57 (17.60) 1.09 (0.69) 0.044
0.9 [0.9; 1.76] 0.9 [0.9; 0.9]
0.9 to 81.14 0.9 to 4.53
CME (n = 38) no CME (n = 20)
IL-10 (ρg/ml) 1.29 (1.17) 2.28 (3.33) 0.012
1.1 [1.1; 1.1] 1.1 [1.1; 1.32]
1.1 to 8.21 1.1 to 12.12
enlarged FAZ (n = 6) physiological FAZ (n = 36)
IL-8 (ρg/ml) 30.17 (38.69) 9.64 (6.18) 0.031
15.49 [10.73; 25.10] 9.05 [5.02; 12.01]
6.17 to 108.03 0.82 to 30.33
VEGF (ρg/ml) 794.54 (1227.54) 158.55 (239.81) 0.031
374.07 [152.32; 571.07] 26.3 [26.3; 211.52]
26.3 to 3269.42 26.3 to 925.66
Variables are described (above to lower) by mean and standard deviation, median and interquartilic range [percentiles 25th, 75th], and absolute range.
Abbreviations: CME, cystoid macular edema; DRT, diffuse retinal thickening; DME, diabetic macular edema; FAZ, foveal avascular zone; n, number of
cases; OCT, optical coherence tomography; UWFA, ultra-widefield fluorescein angiography.
https://doi.org/10.1371/journal.pone.0173865.t003
Fig 4. Boxplot graphic showing statistically significant differences (*) regarding peripheral blood
inflammatory mediators and OCT and UWFA DME-associated items. (A) Increased IL-6 levels
associated to DRT. (B) Decreased IL-10 levels related to CME. (C) Increased IL-8 and VEGF concentration
(D) associated to enlarged FAZ.
https://doi.org/10.1371/journal.pone.0173865.g004
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attending the primary care ophthalmologist. Therefore their comparision with DME patients
could be inaccurate. Regarding serum inflammatory markers, one could expect some relation-
ship with DME as intraocular levels are indeed increased in DME. [20] However, none of
them did statistically differ between groups. Although levels of TNF-α showed a higher con-
centration in DME patients (median 7.58 ρg/ml) than non-DME ones (median 5.74 ρg/ml),
such a difference did not match the established significance level (p = 0.078). A recent pub-
lished study [26] reached similar conclusions when reporting increased serum levels of TNF-α
in DME patients. However, such a finding was only statistically significant when comparing
levels on DME patients to healthy non-DM controls. [26]. Moreover, this difference was not
significant when comparing DME cases with either DR patients with no-DME, or DM patients
with no DR. [26].
In the second part of the study we focused on the DME group to identify associations
between certain clinical and anatomical characteristics of DME cases and systemic levels of
several factors. We therefore selected defined endpoints that may influence DME prognosis
and can be easily determined by objective explorations. BCVA, although a major clinical out-
come of DME, was not one of these items since it can be easily biased by other parameters
such as DME duration, presence of cataract and macular ischemia. However, in the present
study, BCVA remained a good marker of internal validity as was significantly (p = 0.001)
higher in mild DME cases (CST<450μm) than severe ones (CST450μm).
Regarding OCT-based items, we could first expect increased CST to be associated to higher
levels of inflammatory serum mediators. Despite that, no differences were found regarding
serum cytokines and other molecules between mild DME cases (CST<450μm) and severe
ones (CST450μm). Such a finding may reinforce the idea that the systemic inflammatory
milieu does not completely explain DME behaviour. The fact that DME patients present with
mild or severe forms could be therefore related in fact to the intraocular concentration of such
molecules. Some of the other OCT-based qualitative findings (DRT, CME, SRD and ERM)
have been indeed interestingly associated to intraocular levels of inflammatory mediators. [27,
28] DME with DRT is thought to be related to poor glycemic control and poor response to
treatment. Our analysis showed increased serum levels of IL-6 in patients with DRT (Table 3,
Fig 4). IL-6 is a multifunctional cytokine essential for acute phase reactions and regulation of
immune processes known to be involved in both increased vascular permeability and angio-
genesis.[28–30] Such a finding could support the idea of a strong inflammatory nature of this
macular feature. Moreover, high blood levels of IL-6 have already been reported to be associ-
ated to severe grades of DR itself,[14] commonly found together with DRT cases of DME in
DM patients with poor glycemic control. Another studied item was CME, which stands for
certain cases of DME presenting with major intraretinal cysts within inner retinal layers.
Regarding CME, no differences between cytokines were found, except for IL-10, which was
significantly decreased in the DME group (Table 3, Fig 4). IL-10 is a pleiotropic immunosup-
pressive and immunostimulatory cytokine which is able to down-regulate inflammatory activ-
ity of T lymphocytes helper 1.[20, 27, 31, 32] In addition, it also prevents angiogenesis by
downregulating VEGF. [27, 32] To our knowledge, there have not been previous reports on
systemic IL-10 in DR nor DME. However, some studies did report low AH concentration of
IL-10 in DR and even DME [20, 32]. Our results would suggest that low IL-10 blood levels
could be related to CME findings in DME. Finally, as OCT-based items, SRD and ERM were
also studied. SRD stands for an anatomical subtype of edema with subretinal location of fluid
caused by breakdown of the outer BRB. [27, 28] ERM, in turn, stands for epithelial prolifera-
tion on the inner surface of the retina. No differences were found between patients with and
without these features, most likely due to the small number of cases with either SRD (n = 7) or
ERM (n = 4).
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Regarding UWFA findings, studied items included pattern of DME, enlarged FAZ and PRI.
No significant differences were found between focal and diffuse DME pattern in any of the
analysed markers. This could therefore enforce current theories on edema location within the
macula being mainly driven by local factors instead of systemic ones. We also analysed two
other items by UWFA: PRI and enlarged FAZ. PRI depicted by UWFA could be a way to char-
acterize retinal microangiopathy and tissue ischemia in DM. PRI is nowadays a topic of major
importance due to its presumed involvement in DME formation and maintenance; Wessel et al.
[33] found 83% of studied DME cases to be associated to PRI with a statistically significant odds
ratio of 3.75 when compared to PRI in DR non-DME subjects. In our studied DME group, only
26% of DME cases did present with PRI on UWFA. More reports are needed to confirm this
point. Regarding PRI, peripheral blood mediators did not match significance level.
The avascular zone of the central retina (fovea) is known as FAZ. An enlarged FAZ in DME
patients is presumed to be associated to certain grades of macular ischemia and therefore poor
visual prognosis. Moreover, FAZ itself has been directly correlated to PRI in some UWFA-
based reports.[25] Interestingly, we found that peripheral blood levels of IL-8 and VEGF were
statistically higher in enlarged FAZ DME cases (Table 3, Fig 4). The pro-inflammatory chemo-
kine IL-8 is a major attractant and activator of neutrophils and T lymphocites. Its increased
levels have been associated to advanced stages of DR such as PDR due to vessel gliotic oblitera-
tion.[32]. VEGF, perhaps the most studied and well-known growth factor in DR, is an endo-
thelial cell mitogen inducing vascular permeability and angiogenesis.[32] Increased IL-8 and
VEGF in DME cases with enlarged FAZ could suggest central retinal vasculopathy cases to be
somehow systemic-related. However, lack of statistical significance regarding PRI findings
does not allow a better knowledge on how serum inflammatory mediators associate to DME
and local vascular-related events.
As a final point of discussion it is mandatory to take into consideration the limitations of
the present investigation. Although designed on a proof of concept basis, the cross-sectional
nature of the study limits the extent of the conclusions. Reduced sample size and variability of
cytokines and growth factors remain as main limitations. In addition, lack of correction for
multiple comparisons could affect the study power to detect differences. Therefore, our find-
ings should be validated in posterior independent studies and the reported associations should
be carefully considered. More studies are warranted with increased group sizes in order to fur-
ther understand the involvement of systemic mediators in DME.
Conclusion
The results of our study suggest that inflammatory and metabolic serum mediators are not dif-
ferentially associated to DME when compared to non-DME patients. However, we do report
several OCT and UWFA features of DME such as DRT, CME and enlarged FAZ to be associ-
ated to certain systemic inflammatory mediators. Given that DME is a multifactorial condition
resulting from complex interactions of both systemic and local inflammatory events, such
findings could be of major importance as a starting point to further investigate the contribu-
tion of systemic inflammation in DME.
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